Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 3, 2005, Pages 943-951

  Grygielko, Eugene T ^a   Martin, William M ^a   Tweed, Christopher ^a   Thornton, Peter ^a   Harling, John ^b   Brooks, David P ^a   Laping, Nicholas J ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 TERT BUTYL 5 (6 METHYLPYRIDIN 2 YL) 1H IMIDAZOL 4 YL]QUINOXALINE; ACTIVIN RECEPTOR LIKE KINASE 2; ACTIVIN RECEPTOR LIKE KINASE 3; ACTIVIN RECEPTOR LIKE KINASE 4; ACTIVIN RECEPTOR LIKE KINASE 6; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN; PROCOLLAGEN ALPHA1; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PUROMYCIN AMINONUCLEOSIDE; QUINOXALINE DERIVATIVE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN A498; DOSE RESPONSE; DRUG POTENCY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MARKER GENE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RAT;

ACTIVIN RECEPTORS; ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HUMANS; KIDNEY; NEPHRITIS; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN-SERINE-THREONINE KINASES; PUROMYCIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 19444371555     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.082099     Document Type: Article

References (28)

1. Border WA (1992) Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature (Lond) 360:361-364.
2. Border WA and Noble NA (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 10:1286-1292.
3. Border WA, Okuda S, Languino LR, Sporn MB, and Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta1. Nature (Lond) 346:371-374.
4. Bottinger EP and Bitzer M (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13:2600-2610.
5. Bottinger EP and Kopp JB (1998) Lessons from TGF-beta transgenic mice. Miner Electrolyte Metab 24:154-160.
6. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, et al. (2002) Identification of novel inhibitors of the transforming growth factor-beta type I receptor (ALK5). J Med Chem 45:999-1001.
7. Chandra M, Susin M, Teichberg S, and McVicar M (1984) Experimental focal segmental glomerulosclerosis: correlation with protein excretion, glomerular filtration rate and renal plasma flow. Pediatr Res 18:1195-1201.
8. Ding G, Van Goor H, Frye J, and Diamond JR (1994) Transforming growth factor-beta expression in macrophages during hypercholesterolemic states. Am J Physiol 267:F937-F943.
9. Eddy AA (1994) Protein restriction reduces transforming growth factor-beta and interstitial fibrosis in nephrotic syndrome. Am J Physiol 266:F884-F893.
10. Eddy AA and Michael AF (1988) Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int 33:14-23.
11. George J, Wang SS, Sevcsik AM, Sanicola M, Cate RL, Koteliansky VE, and Bissell DM (2000) Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am J Pathol 156:115-124.
12. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, Matsumoto K, and Nishida E (1999) Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 274:27161-27167.
13. Heldin CH, Miyazono K, and ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (Lond) 390:465-471.
14. Jones CL, Buch S, Post M, McCulloch L, Liu E, and Eddy AA (1992) Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 141:1381-1396.
15. Kawano H, Kim S, Ohta K, Nakao T, Miyazaki H, Nakatani T, and Iwao H (2003) Differential contribution of three mitogen-activated protein kinases to PDGF-BB-induced mesangial cell proliferation and gene expression. J Am Soc Nephrol 14:584-592.
16. Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, and Wiggins R (2001) Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60:957-968.
17. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, and Thorgeirsson SS (1996) Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Investig 74:991-1003.
18. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, et al. (2002) Inhibition of transforming growth factor (TGF)-beta 1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64.
19. Ma LJ, Jha S, Ling H, Pozzi A, Ledbetter S, and Fogo AB (2004) Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int 65:106-115.
20. Massague J (1996) TGF-beta signaling: receptors, transducers and Mad proteins. Cell 85:947-950.
21. Roberts AB, McCune BK, and Sporn MB (1992) TGF-beta: regulation of extracellular matrix. Kidney Int 41:557-559.
22. Sharma K, Jin Y, Guo J, and Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530.
23. ten Dijke P, Ichijo H, Franzen P, Schulz P, Saras J, Toyoshima H, Heldin CH, and Miyazono K (1993) Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 8:2879-2887.
24. Van Goor H, Diamond JR, and Grond J (1993) Renal disease induced in rats by puromycin aminonucleoside, in Experimental and Genetic Rat Models of Chronic Renal Failure (Gretz N and Strauch M, eds) pp 68-81, Karger AG, Basel, Switzerland.
25. Wrana JL (1998) TGF-beta receptors and signalling mechanisms. Miner Electrolyte Metab 24:120-130.
26. Yamazaki T (1995) Podocytic degeneration and regeneration in puromycin aminonucleoside nephropathy in the rat. Path Int 45:465-472.
27. Zhan YM, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, and Iwao H (2003) Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration and gene expression. Arterioscler Thromb Vasc Biol 23:795-801.
28. Ziyadeh FN and Sharma K (1996) The use of neutralizing antibodies to demonstrate the role of transforming growth factor-beta and Amadori-glycated albumin as mediators of experimental diabetic kidney disease. Contr Nephrol 118:188-194.